Bazedoxifene (Wyeth).
Bazedoxifene is a tissue-specific selective estrogen receptor modulator being developed by Wyeth Pharmaceuticals (formerly Wyeth-Ayerst Laboratories) to be used alone for the prevention and treatment of osteoporosis in postmenopausal women and in combination with Premarin for menopausal symptoms. As of March and June 2004, worldwide phase III trials for bazedoxifene, and bazedoxifene in combination with Premarin, were ongoing.
Gruber
Christian
C
Department of Gynecological Endocrinology and Reproductive Medicine, University of Vienna Medical School, A-1090 Vienna, Wahringer Gurtel 18-20, Austria. christian_gruber@chello.at
Gruber
Doris
D
D000818:Animals; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000378:metabolism / Q000517:prevention & control; D011960:Receptors, Estrogen / Q000378:metabolism; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013329:Structure-Activity Relationship; D016896:Treatment Outcome
D007211:Indoles; D011960:Receptors, Estrogen; D020845:Selective Estrogen Receptor Modulators; C447119:bazedoxifene